A new demonstration facility in New York gives Sartorius’ customers hands-on access to bioprocessing systems and lab instruments.
Mary Lavin, president of the Sartorius companies in North America, leads the ribbon cutting ceremony at the company’s New York Sartorius Application Center in Bohemia. Town of Islip Supervisor Angie M. Carpenter (left), members of the Sartorius Executive Committee, and local officials participated in the ceremony. Photo courtesy of Sartorius.
Sartorius has opened its first North American demonstration laboratory in Bohemia, NY to provide customers with access to the company’s upstream and downstream processing systems and laboratory products. The laboratory, part of the company’s new 40,000-sq-ft facility, features hands-on demonstration stations, as well as classroom learning space.
The Long Island-based Sartorius Application Center is modeled after similar application centers in China and Germany. In the FlexLab, customer can view FlexAct systems, Sartocheck bag testers, and TAP Biosystems equipment. Laboratory products on display include scales, balances, and liquid handling systems. In addition, an R&D section showed developments in bioreactors and freeze/thaw equipment.
At a grand opening event on June 2, Sartorius hosted customers, employees, the media, and local government officials for a ribbon-cutting ceremony and facility tours with introductions provided by Mary Lavin, the company’s president for North America.
Source: Sartorius
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 2nd 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.